Back to News
Market Impact: 0.32
Immutep Limited - Depositary Receipt Price Target Increased by 917.93% to $69.75
Source: Nasdaq
Analyst EstimatesAnalyst InsightsHealthcare & Biotech
The aggregate one-year analyst price target for Immutep's NASDAQ-listed depositary receipts (IMMP) was raised to $69.75 per share from $6.85, a 917.93% increase versus the prior estimate dated September 13, 2026. The exceptionally large upward revision signals sharply improved analyst expectations and could materially support sentiment toward the biotech stock, though the article does not provide underlying earnings, clinical, or operational catalysts.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.72
Ticker Sentiment
IMMP0.82
More News
- Your health insurance premiums may take a big jump in 2027 — here's why
- Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals
- Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
- Tesla reports 486,532 vehicle deliveries for third quarter, topping expectation
- Why AMD Stock Jumped 30% in September
- Nike falls to 13-year low. Why analysts don't think the selling is over yet
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- What Exactly Does Post-Training in LLMs and Finance-Focused AI Actually Mean for Asset Managers?
- What Is a Financial Ontology?